EGFR Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

Lignende værker

• EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study
  af: Bernardes, Vanessa Fátima, et al.
  Udgivet: (2013)
• Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas
  af: Sholl, Lynette M., et al.
  Udgivet: (2013)
• Brief report: EGFR L858M/L861Q cis mutations confer selective sensitivity to afatinib
  af: Saxon, Jamie A., et al.
  Udgivet: (2017)
• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  af: Nishino, Mizuki, et al.
  Udgivet: (2012)
• RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
  af: Nishino, Mizuki, et al.
  Udgivet: (2013)